Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• HendersonBEFeigelsonHSHormonal carcinogenesisCarcinogenesis200021342743310688862
   PubMed Web of Science ®Google Scholar
• YagerJDEndogenous estrogens as carcinogens through metabolic activationJ Natl Cancer Inst Monogr200027677310963620
   PubMedGoogle Scholar
• CavalieriEFrenkelKLiehrJGRoganERoyDEstrogens as endogenous genotoxic agents – DNA adducts and mutationsJ Natl Cancer Inst Monogr200027759310963621
   PubMedGoogle Scholar
• BeatsonGTOn the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative casesThe Lancet18962104107
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative GroupEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• DowsettMHaynesBPHormonal effects of aromatase inhibitors: Focus on premenopausal effects and interaction with tamoxifenJ Steroid Biochem Mol Biol2003863–525526314623519
   PubMed Web of Science ®Google Scholar
• CasperRFMitwallyMFReview: aromatase inhibitors for ovulation inductionJ Clin Endocrinol Metab200691376077116384846
   PubMed Web of Science ®Google Scholar
• NelsonLRBulunSEEstrogen production and actionJ Am Acad Dermatol200145Suppl 3S116S12411511861
   PubMed Web of Science ®Google Scholar
• SimpsonERSources of estrogen and their importanceJ Steroid Biochem Mol Biol2003863–522523014623515
   PubMed Web of Science ®Google Scholar
• PasqualiniJRChetriteGBlackerCConcentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patientsJ Clin Endocrinol Metab1996814146014648636351
   PubMed Web of Science ®Google Scholar
• AgarwalVRBulunSELeitchMRohrichRSimpsonERUse of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patientsJ Clin Endocrinol Metab19968111384338498923826
   PubMed Web of Science ®Google Scholar
• ChetriteGSCortes-PrietoJPhilippeJCWrightFPasqualiniJRComparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissuesJ Steroid Biochem Mol Biol2000721–2232710731634
   PubMed Web of Science ®Google Scholar
• LønningPEGeislerJBhatnagerADevelopment of aromatase inhibitors and their pharmacologic profileAm J Clin Oncol2003264 Suppl 1S3S812902871
   PubMed Web of Science ®Google Scholar
• DombernowskyPSmithIFalksonGLetrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetateJ Clin Oncol19981624534619469328
   PubMed Web of Science ®Google Scholar
• KaufmannMBajettaEDirixLYExemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study GroupJ Clin Oncol20001871399141110735887
   PubMed Web of Science ®Google Scholar
• BuzdarADoumaJDavidsonNPhase III, multicenter, doubleblind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetateJ Clin Oncol200119143357336611454883
   PubMed Web of Science ®Google Scholar
• NabholtzJMBuzdarAPollakMAnastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study GroupJ Clin Oncol200018223758376711078488
   PubMed Web of Science ®Google Scholar
• BonneterreJThurlimannBRobertsonJFAnastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability studyJ Clin Oncol200018223748375711078487
   PubMed Web of Science ®Google Scholar
• BonneterreJBuzdarANabholtzJMAnastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer20019292247225811745278
   PubMed Web of Science ®Google Scholar
• MouridsenHGershanovichMSunYPhase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer GroupJ Clin Oncol200321112101210912775735
   PubMed Web of Science ®Google Scholar
• ParidaensRJDirixLYBeexLVPhase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupJ Clin Oncol200826304883489018794551
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Version 2.20112011
   Google Scholar
• Harper-WynneCCoombesRCAnastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapyEur J Cancer199935574474610505035
   PubMed Web of Science ®Google Scholar
• ChiaSGradisharWMauriacLDouble-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECTJ Clin Oncol200826101664167018316794
   PubMed Web of Science ®Google Scholar
• LønningPEBajettaEMurrayRActivity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trialJ Clin Oncol200018112234224410829043
   PubMed Web of Science ®Google Scholar
• CarliniPMichelottiAFerrettiGClinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patientsCancer Invest200725210210517453821
   PubMed Web of Science ®Google Scholar
• BursteinHJPrestrudAASeidenfeldJAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancerJ Clin Oncol201028233784379620625130
   PubMed Web of Science ®Google Scholar
• WinerEPHudisCBursteinHJAmerican Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004J Clin Oncol200523361962915545664
   PubMed Web of Science ®Google Scholar
• CuzickJSestakIBaumMEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialLancet Oncol201011121135114121087898
   PubMed Web of Science ®Google Scholar
• MouridsenHGiobbie-HurderAGoldhirschALetrozole therapy alone or in sequence with tamoxifen in women with breast cancerN Engl J Med2009361876677619692688
   PubMed Web of Science ®Google Scholar
• BaumMBudzarAUCuzickJAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialLancet200235993242131213912090977
   PubMed Web of Science ®Google Scholar
• ThurlimannBKeshaviahACoatesASA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med2005353262747275716382061
   PubMed Web of Science ®Google Scholar
• DowsettMCuzickJIngleJMeta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifenJ Clin Oncol201028350951819949017
   PubMed Web of Science ®Google Scholar
• CoombesRCKilburnLSSnowdonCFSurvival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialLancet2007369956155957017307102
   PubMed Web of Science ®Google Scholar
• JakeszRJonatWGnantMSwitching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trialLancet2005366948445546216084253
   PubMed Web of Science ®Google Scholar
• JakeszRGnantMGreilRTamoxifen and anstrozole as sequencing strategy in post menopausal women with hormone-responsive breast cancer: up date from the Austrian Breast and Colorectal Cancer Study Group Trial 8Abstract presented at the 31st Annual San Antonio Breast Cancer SymposiumSan Antonio, TX Abstract 14December 10–14, 2008
   Google Scholar
• BoccardoFRubagottiAGuglielminiPSwitching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trialAnn Oncol200617Suppl 7vii10vii1416760270
   PubMed Web of Science ®Google Scholar
• KaufmannMJonatWHilfrichJImproved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 StudyJ Clin Oncol200725192664267017563395
   PubMed Web of Science ®Google Scholar
• van de VeldeCJReaDSeynaeveCAdjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialLancet2011377976232133121247627
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSRandomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17J Natl Cancer Inst200597171262127116145047
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNPaterJLLate extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenJ Clin Oncol200826121948195518332475
   PubMed Web of Science ®Google Scholar
• MamounasEPJeongJHWickerhamDLBenefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trialJ Clin Oncol200826121965197118332472
   PubMed Web of Science ®Google Scholar
• GeislerJHaynesBAnkerGDowsettMLønningPEInfluence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over studyJ Clin Oncol200220375175711821457
   PubMed Web of Science ®Google Scholar
• GeislerJKingNAnkerGIn vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patientsClin Cancer Res199849208920939748124
   PubMed Web of Science ®Google Scholar
• GeislerJDifferences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?Br J Cancer201110471059106621364577
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNChapmanJ-AWFinal analysis of NCIC CTG MA.27: A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancerAbstract presented at the 33rd Annual San Antonio Breast Cancer SymposiumSan Antonio, TX Abstract S1–1December 6–10, 2010
   Google Scholar
• O’ShaughnessyJA decade of letrozole: FACEBreast Cancer Res Treat2007105Suppl 1677417912637
   PubMed Web of Science ®Google Scholar
• HowellAAdjuvant aromatase inhibitors for breast cancerLancet2005366948443143316084234
   PubMed Web of Science ®Google Scholar
• DentSFGaspoRKissnerMPritchardKIAromatase inhibitor therapy: Toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancerBreast Cancer Res Treat2011126229531021249443
   PubMed Web of Science ®Google Scholar
• CellaDFallowfieldLBarkerPCuzickJLockerGHowellAQuality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancerBreast Cancer Res Treat2006100327328416944295
   PubMed Web of Science ®Google Scholar
• WhelanTJGossPEIngleJNAssessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal womenJ Clin Oncol200523286931694016157934
   PubMed Web of Science ®Google Scholar
• BuzdarAHowellACuzickJComprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trialLancet Oncol20067863364316887480
   PubMed Web of Science ®Google Scholar
• PartridgeAHLaFountainAMayerETaylorBSWinerEAsnis-AlibozekAAdherence to initial adjuvant anastrozole therapy among women with early-stage breast cancerJ Clin Oncol200826455656218180462
   PubMed Web of Science ®Google Scholar
• AmirEOncañaANiraulaSCarlssonLSerugaBToxicity of adjuvant endocrine therapy in postmenopausal breast cancer patientsAbstract presented at the 33rd Annual San Antonio Breast Cancer SymposiumSan Antonio, TX Abstract S2–7December 6–10, 2010
   Google Scholar
• ColemanREBanksLMGirgisSIReversal of skeletal effects of endocrine treatments in the Intergroup Exemestane StudyBreast Cancer Res Treat2010124115316120730486
   PubMed Web of Science ®Google Scholar
• LigbielJAO’MalleyAFisherMDanielGWinerEPKeatingNLAromatase inhibitors and risk of myocardial infarction, stroke and fractureAbstract presented at the 33rd Annual San Antonio Breast Cancer SymposiumSan Antonio, TX Abstract S2–6December 6–10, 2010
   Google Scholar
• BrufskyAMBossermanLDCaradonnaRRZoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up resultsClin Breast Cancer200992778519433387
   PubMed Web of Science ®Google Scholar
• HillnerBEIngleJNChlebowskiRTAmerican Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancerJ Clin Oncol200321214042405712963702
   PubMed Web of Science ®Google Scholar
• HadjiPBodyJJAaproMSPractical guidance for the management of aromatase inhibitor-associated bone lossAnn Oncol20081981407141618448451
   PubMed Web of Science ®Google Scholar
• MouridsenHKeshaviahACoatesASCardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1–98 trialJ Clin Oncol200725365715572217998546
   PubMed Web of Science ®Google Scholar
• CupponeFBriaEVermaSDo adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trialsCancer2008112226026718041059
   PubMed Web of Science ®Google Scholar
• MussHBTuDIngleJNEfficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17J Clin Oncol200826121956196418332474
   PubMed Web of Science ®Google Scholar
• ZidanJChetverLHusseinOZuckerMEffect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancerOncologist201015111159116320980416
   PubMed Web of Science ®Google Scholar